Home-based mobile neurological check for people with brain tumors
Official title: Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
Run by Tata Memorial Centre · NCT07236840 · Data updated 2026-11-12
This project will test whether people with brain tumors older than 5 can use the Iskhaa Android app to do guided self-neurological exams, upload short videos, and have an AI model detect changes that might predict neurological worsening.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Tata Memorial Centre Academic / other |
| Locations | 1 site (Mumbai, Maharashtra) |
| Status | Recruiting |
| Started | February 20, 2026 |
| Main results expected | November 1, 2027 |
| Study ends | November 5, 2027 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT07236840 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are people aged over 5 with a radiologic or histologic diagnosis of a brain tumor, an expected survival over six months, able to follow app instructions, and who or whose caregiver can install and use an Android smartphone app.
✕Probably not a fit
Patients with severe cognitive or psychiatric impairment, KPS/LPS below 50, expected survival under six months, unreliable caregivers, or no access to a compatible Android smartphone are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study develops and deploys the Iskhaa mobile application to guide patients through self-administered neurological tasks (speech, gait, limb movements) with pre-recorded video instructions and video recording. Data and videos will be stored on a secure hospital server and reviewed by investigators via mobile or desktop interfaces, while participants also complete EORTC QLQ-C30 and BN20 quality-of-life questionnaires. An AI model will be trained and validated on the recorded features to detect functional changes and predict subsequent neurological deterioration. The initial phase includes supervised onsite use (about 100 participants) at Tata Memorial Centre with subsequent remote use for eligible participants.
Why it matters
Potential benefit: If successful, the app plus AI could enable earlier detection of neurological decline and more convenient remote monitoring for people with brain tumors.
How similar studies have gone: Smartphone and video-based neurological assessments have shown promise in other neurological conditions, but using recorded videos plus AI to predict deterioration specifically in brain tumor patients remains largely exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosis of brain tumors (histopathology/ radiology). 2. Age \> 5 years 3. Patient or caregiver have access to an android smart phone and is able to install the mobile application. 4. Expected survival more than 6 months during study accrual. 5. Signing patient consent or parent consent/ child assent form (as appropriate). Exclusion Criteria: 1. Patient or caregiver is not reliable to follow instructions or use the mobile application. 2. Patient with severe cognitive or psychiatric issues causing difficulty in using the app or follow instructions. 3. Karnofsky Performance Status (KPS) or Lansky Performance Status LPS) \<50. 4. Terminal illness with expected life expectancy (\<6 months).
Where it's running
-
Tata Memorial Centre
Mumbai, Maharashtra, India Recruiting
Study contacts
- Study coordinator: Dr Archya Dasgupta, Radiation Oncology, MD
- Email: archya1010@gmail.com
- Phone: 8097081506
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted whole-course management for safe medicine use in advanced solid tumors
A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Digitally Enabled Districts 2.0: Aimed at Improving Maternal and Neonatal Care in Garut
A stepped-wedge trial tests whether an integrated digital health ecosystem helps 45 local clinics in Garut improve the completeness and timeliness of maternal and neonatal care.
-
Preventing another ischemic stroke with a smart bracelet and app
This study tests whether a digital prevention program using a wearable and a mobile app can help people who recently had an ischemic stroke reduce the chance of another stroke and improve risk-factor control.
-
AI-assisted and traditional workflows for admission diagnosis and management planning
This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.